Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Canaan Partners
Deal Size : $150.0 million
Deal Type : Series D Financing
CatalYm cashes in on early-stage cancer data with $150M series D
Details : The Proceeds will expand CTL-002 (visugromab) late-stage clinical development into earlier lines of treatment in combination with nivolumab for the treatment of bladder cancer.
Product Name : CTL-002
Product Type : Antibody
Upfront Cash : Undisclosed
July 16, 2024
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Canaan Partners
Deal Size : $150.0 million
Deal Type : Series D Financing
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CatalYm Reports Lasting Responses in Late-Line NSCLC and Other Cancer Patients
Details : CTL-002 (visugromab) is a monoclonal antibody that neutralizes GDF-15 is being investigated in combination with nivolumab, a PD-1 inhibitor) in R/R non-small cell lung cancer (MIBC).
Product Name : CTL-002
Product Type : Antibody
Upfront Cash : Inapplicable
February 06, 2024
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTL-002 (Visugromab) is a monoclonal antibody that neutralizes the tumor-derived Growth Differentiation Factor-15 (GDF-15) in combination with neoadjuvant immunotherapy (nivolumab, aPD-1 inhibitor) in muscle invasive bladder cancer (MIBC).
Product Name : CTL-002
Product Type : Antibody
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Brandon Capital
Deal Size : $51.8 million
Deal Type : Series C Financing
Details : The financing will support the continued, promising clinical development of its lead candidate, visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).
Product Name : CTL-002
Product Type : Antibody
Upfront Cash : Undisclosed
November 22, 2022
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Brandon Capital
Deal Size : $51.8 million
Deal Type : Series C Financing
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Visugromab, formerly known as CTL-002, is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).
Product Name : CTL-002
Product Type : Antibody
Upfront Cash : Inapplicable
October 09, 2022
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Visugromab, formerly known as CTL-002, is a monoclonal antibody that neutralizes GDF-15, a key immunosuppressor, which has been shown to prevent T cell migration into tumors, enabling cancerous cells to evade the immune system.
Product Name : CTL-002
Product Type : Antibody
Upfront Cash : Inapplicable
September 26, 2022
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Visugromab, formerly known as CTL-002, is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).
Product Name : CTL-002
Product Type : Antibody
Upfront Cash : Inapplicable
May 09, 2022
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The GDFATHER-2 trials, will evaluate safety and efficacy of CTL-002, mAB designed to neutralize tumor-produced GDF-15, at confirmed target dose in combination with nivolumab in tumor patients to anti-PD1/-L1 treatment and in one cohort that is anti-PD-1/...
Product Name : CTL-002
Product Type : Antibody
Upfront Cash : Inapplicable
January 03, 2022
Details : CatalYm’s CTL-002 demonstrate clinical proof-of-concept in multiple solid tumor indications which will expand the treatment for current and future immunotherapies. CTL-002 is a humanized, monoclonal antibody designed to neutralize the tumor-produced GD...
Product Name : CTL-002
Product Type : Antibody
Upfront Cash : Inapplicable
November 10, 2021
Details : CTL-002 is a humanized, monoclonal antibody designed to neutralize tumor-produced Growth Differentiation Factor-15 by enhancing infiltration of immune cells into tumor, improving both priming of T cells by dendritic cells and tumor killing by T cells and...
Product Name : CTL-002
Product Type : Antibody
Upfront Cash : Inapplicable
September 30, 2021
Reset All
